Clinical development of a Vero cell culture-derived seasonal influenza vaccine

Vaccine

Volumn 30, Issue 29, 2012, Pages 4377-4386

  Ehrlich, Hartmut J ^a   Berezuk, Gregory ^b   Fritsch, Sandor ^a   Aichinger, Gerald ^a   Singer, Julia ^a   Portsmouth, Daniel ^a   Hart, Mary Kate ^c   El Amin, Wael ^c   Kistner, Otfried ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Baxter BioScience   (United States)

^c A CSC Company   (United States)

Author keywords

Clinical trial; Influenza; Influenza vaccine; Seasonal influenza; Vaccine efficacy; Vero cell culture derived vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; CELL CULTURE; CHILL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGG; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HYPERHIDROSIS; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORTHERN HEMISPHERE; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SEROLOGY; VERO CELL;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VERO CELLS; YOUNG ADULT;

EID: 84861981761     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.114     Document Type: Article

References (56)

1. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008, 26(Suppl. 4):D31-D34.
2. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
3. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26(Suppl. 4):D5-D9.
4. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61:94-99.
5. Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2000, 49:619-622.
6. Makizumi K., Kimachi K., Fukada K., Nishimura T., Kudo Y., Goto S., et al. Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 2008, 26:6852-6858.
7. Widjaja L., Ilyushina N., Webster R.G., Webby R.J. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 2006, 350:137-145.
8. Pearson H. US lacks back-up for flu vaccine shortfall. Nature 2004, 431:726.
9. Tiered use of inactivated influenza vaccine in the event of a vaccine shortage. MMWR Morb Mortal Wkly Rep 2005, 54:749-750.
10. Fink S. Aches and pains. Learning lessons from the influenza vaccine shortage. IAVI Rep 2004, 9:10-11.
11. Minor P.D. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010, 50:560-565.
12. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009, 8:607-618.
13. Katz J.M., Wang M., Webster R.G. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990, 64:1808-1811.
14. Schild G.C., Oxford J.S., de Jong J.C., Webster R.G. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983, 303:706-709.
15. Robertson J.S., Bootman J.S., Newman R., Oxford J.S., Daniels R.S., Webster R.G., et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 1987, 160:31-37.
16. Katz J.M., Webster R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989, 160:191-198.
17. Wood J.M., Oxford J.S., Dunleavy U., Newman R.W., Major D., Robertson J.S. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 1989, 171:214-221.
18. Patriarcha P.A. Use of cell lines for the propagation of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations 2007, World Health Organization, Available from: http://www.who.int/vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf (accessed 9.06.11).
19. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
20. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.
21. Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
22. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 2010, 12:21-30.
23. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, 1997. Report No.: CPMP/BWP/214/96.
24. FDA/CBER Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines 2007, US Food and Drug Administration, Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf (accessed 9.06.11).
25. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
26. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
27. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
28. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008, 57:1-60.
29. Wichmann B.A., Hill I.D. Algorithm 183. An efficient and portable pseudo-random number generator. Appl Stat 1982, 31:188-190.
30. Mcleod A. Remark AS R58. A remark on algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 1985, 121:811-822.
31. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
32. Barford K. Estimation of optimal cutoff for ELISA assays using latent class methods and ROC analysis. Proceedings of the 11th International Symposium on Veterinary Epidemiology and Economics 2006.
33. Update: influenza activity - United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:369-374.
34. Jefferson T., Di P.C., Rivetti A., Bawazeer G.A., Al-Ansary L.A., Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010, 7:CD001269.
35. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51:997-1004.
36. Jackson L.A., Gaglani M.J., Keyserling H.L., Balser J., Bouveret N., Fries L., et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010, 10:71.
37. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
38. Perdue M.L., Arnold F., Li S., Donabedian A., Cioce V., Warf T., et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines 2011, 10:1183-1194.
39. Baxter R., Patriarca P.A., Ensor K., Izikson R., Goldenthal K.L., Cox M.M. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011, 29:2272-2278.
40. King J.C., Cox M.M., Reisinger K., Hedrick J., Graham I., Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009, 27:6589-6594.
41. Treanor J.J., El S.H., King J., Graham I., Izikson R., Kohberger R., et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29:7733-7739.
42. Ambrozaitis A., Groth N., Bugarini R., Sparacio V., Podda A., Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009, 27:6022-6029.
43. Groth N., Montomoli E., Gentile C., Manini I., Bugarini R., Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009, 27:786-791.
44. Szymczakiewicz-Multanowska A., Groth N., Bugarini R., Lattanzi M., Casula D., Hilbert A., et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009, 200:841-848.
45. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
46. Beran J., Wertzova V., Honegr K., Kaliskova E., Havlickova M., Havlik J., et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009, 9:2.
47. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
48. Kumar R., Burns E.A. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008, 7:467-479.
49. Palache A.M., Brands R., van Scharrenburg G.J. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(Suppl 1):S20-S23.
50. Voordouw A.C., Beyer W.E., Smith D.J., Sturkenboom M.C., Stricker B.H. Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002. Vaccine 2009, 28:392-397.
51. Seidman J.C., Richard S.A., Viboud C., Miller M.A. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respi Viruses 2011.
52. Reisinger K.S., Block S.L., Izu A., Groth N., Holmes S.J. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009, 200:849-857.
53. Wood J.M., Gaines-Das R.E., Taylor J., Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12:167-174.
54. EMEA Concept paper on the need to update the current annex guideline on cell culture inactivated influenza vaccines with respect to the derivation of cell-isolated influenza vaccine viruses 2009, EMEA, Available from: http://www.emea.europa.eu/pdfs/human/bwp/48147308en.pdf (accessed 13.12.11).
55. Jefferson T., Di P.C., Al-Ansary L.A., Ferroni E., Thorning S., Thomas R.E. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010, CD004876.
56. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.